References
- Allison, A.C., 2000. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology, 47 (2–3), 63–83.
- Amaral, V.C. and Nunes, G.P., Jr., 2009. Prednisone reduces ketoconazole-induced skeletal defects in rat fetuses. Archives of Toxicology, 83 (9), 863–871.
- Armenti, V.T., et al., 2002. Immunosuppression in pregnancy: choices for infant and maternal health. Drugs, 62 (16), 2361–2375.
- Bailey, J., Knight, A., and Balcombe, J., 2005. The Future of Teratology research is in vitro. Biogenic Amines, 19 (2), 97–145.
- Bar, O., et al., 2001. Pregnancy outcome after cyclosporine therapy during pregnancy: a metaanalysis. Transplantation, 71, 1051–1055.
- Blanford, A.T. and Murphy, B.E., 1977. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. American Journal of Obstetrics and Gynecology, 127 (3), 264–267.
- Eckardt, K. and Stahlmann, R., 2010. Use of two validated in vitro tests to assess the embryotoxic potential of mycophenolic acid. Archives of Toxicology, 84 (1), 37–43.
- Framarino dei Malatesta, M., et al., 2011. Successful pregnancy in a living-related kidney transplant recipient who received sirolimus throughout the whole gestation. Transplantation, 91 (9), e69–e71.
- Lessan-Pezeshki, M., 2002. Pregnancy after renal transplantation: points to consider. Nephrology, Dialysis, Transplantation : official Publication of the European Dialysis and Transplant Association – European Renal Association, 17 (5), 703–707.
- Mastrobattista, J.M. and Gomez-Lobo, V, Society for Maternal-Fetal Medicine, 2008. Pregnancy after solid organ transplantation. Obstetrics and Gynecology, 112 (4), 919–932.
- Mele, T.S. and Halloran, P.F., 2000. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology, 47 (2–3), 215–245.
- New, D.A.T., 1978. Whole-embryo culture and the study of mammalian embryos during organogenesis. Biological Reviews of the Cambridge Philosophical Society, 53 (1), 81–122.
- Petri, M., 2003. Immunosuppressive drug use in pregnancy. Autoimmunity, 36 (1), 51–56.
- Rowland, J.M. and Hendrickx, A.G., 1983. Comparative teratogenicity of triamcinolone acetonide, triamcinolone, and cortisol in the rat. Teratogenesis, Carcinogenesis, and Mutagenesis, 3 (4), 313–319.
- Schmid, B.P., 1984. Monitoring of organ formation in rat embryos after in vitro exposure to azathioprine, mercaptopurine, methotrexate or cyclosporin A. Toxicology, 31 (1), 9–21.
- Sifontis, N.M., et al., 2006. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation, 82 (12), 1698–1702.
- Taylor, A.L., Watson, C.J., and Bradley, J.A., 2005. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Critical Reviews in Oncology/Hematology, 56 (1), 23–46.
- Tuchmann-Duplessis, H. and Mercier-Parot, L., 1968. Fetopathie therapeutigues: production experimentale de malformations des membres. Union. Med. Can, 97, 283–288.
- Van Maele-Fabry, G., Delhaise, F., and Picard, J.J., 1990. Morphogenesis and quantification of the development of post-implantation mouse embryos. Toxicology in Vitro : an International Journal Published in Association with BIBRA, 4 (2), 149–156.
- Woodroffe, R., et al., 2005. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technology Assessment, 9 (21), 8–11.
- Zachariah, M.S., Tornatore, K.M., and Venuto, R.C., 2009. Kidney transplantation and pregnancy. Current Opinion in Organ Transplantation, 14 (4), 386–391.